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CytokinesBrain injury induces the expression of well-known cytokines, such as tumor necrosis factor-alpha (TNFα),
and other, which functions are less understood, as secreted phospholipase A2 group IIA (sPLA2-IIA). Since in
pathological processes, cytokines function coordinately in networks, to further explore the actions of sPLA2-
IIA in tumorigenesis, we investigated the effect of sPLA2-IIA in the presence of TNFα in human 1321N1
astrocytoma cells. In these cells, TNFα activates the apoptotic programme that is accompanied of
cytoskeleton changes; however, simultaneous treatment with sPLA2-IIA prevents TNFα-mediated apoptosis
and reverses the modiﬁcation of the markers associated to this response. In fact, the mitogenic activity
elicited by the phospholipase alone is preserved. This inhibitory effect is not found in other TNFα-mediated
responses, even a functional cooperation is observed on COX-2 protein induction. The cross-talk between
TNFα and sPLA2-IIA is associated with ERK activity since its pharmacological inhibition attenuates both
synergistic and inhibitory responses. We have also observed that upon sPLA2-IIA stimulation, endogenous
ERK has the capacity to bind and phosphorylate sequences present within the cytoplasmic domain of TNFR1/
CD120a. These ﬁndings thus indicate that sPLA2-IIA and TNFα transduction pathways interact to modulate
inﬂammatory responses and provide additional insights about the capacity of sPLA2-IIA to promote apoptosis
resistance in astrocytoma cells.
© 2009 Published by Elsevier B.V.1. Introduction
Multiple evidences suggest a link between inﬂammation and CNS
disorders ranging from Alzheimer's or Parkinson's diseases to cancer
[1,2]. Glioblastomas, one of the most common and lethal human
malignancies in the primary CNS, are highly proliferative and invasive
tumors, with poor prognosis despite extensive research and advances
in treatment regimes. Gliomas, compared to systemic neoplasms,
have a high macrophage content [3], which secrete a wide variety of
molecules, including cytokines, that affect survival, growth and
proliferation of the tumors, particularly due to the numerous
receptors expressed by astrocytes that enable them to respond to a
variety of extracellular stimuli [4,5]. Understanding the speciﬁc role
(s) of these components in the evolution of the tumors will be
important for developing new effective therapeutic agents.
Among these factors produced by inﬁltrating monocytes or glial
cells in a feed-forward process [6,7], we can consider the expression ofkinase; JNK, c-Jun N-terminal
xygenase-2; IkB, inhibitory kB
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lsevier B.V.well-known cytokines, such as tumor necrosis factor-alpha (TNF), and
other, which functions are less understood, secreted phospholipase A2
group IIA (sPLA2-IIA).
sPLA2-IIA belongs to a family of enzymes with lipolytic activity
widely distributed in human tissues including brain, where its speciﬁc
function is still largely unclear. Mainly known as an acute phase
protein usually linked to inﬂammatory disorders [8], it can be released
from cells, including monocytes, upon its exposure to proinﬂamma-
tory factors and may act as a convergence molecule involved in the
secondary damage. As result of a brain insult – CNS injuries and
certain neurological disorders – its expression is also enhanced and
associated with reactive astrocytes [9-11], and recent reports show it
up-regulated in human Alzheimer's disease brains [12]. In addition,
increased levels of sPLA2-IIA have been reported in numerous
neoplastic conditions raising the sPLA2-IIA pro-oncogenic activity
concept [13], although its role in tumorigenesis remains controversial.
The precise mechanisms by which secreted PLA2s, and group IIA in
particular, exert their cellular effects are not yet fully understood, but
it has been suggested that some of the biological responses elicited
might involve cytokine-like signaling, independently of their enzy-
matic activity. Thus, it has been shown that upon cell exposure to
sPLA2 several signaling molecules can by regulated, including protein
kinase C, MEK/ERK1/2, p38 MAPK and PI3-K/Akt cascades [14]. In
fact, in 1321N1 human astrocytoma cells, we have described that
exogenous sPLA2-IIA induces phospholipase Cγ-1 activation and Ca2+
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mitogenic response [15,16].
TNFα, one of the best characterized proinﬂammatory cytokines,
can be produced by cells within the CNS or may be originated from
peripheral immune organs and them cross the blood–brain barrier. By
liganding its receptors (CD120a/TNFR1 and CD120b/TNFR2), TNFα
induces the recruitment of adaptor molecules which transmit
downstream signals and, through the activation of different signaling
cascades, mediates a wide variety of biological responses [17-19].
Thus, while the activation of caspases contributes to apoptosis and
participates in the disassembly of cellular structures, such as actin
microﬁlaments [20], the activation of MAPKs and NF-κB leads to the
regulation of relevant genes in survival, inﬂammation and/or cancer
[21,22]. TNFα-mediated activation of NF-κB has been described in
primary cultures and astrocyte cell lines, and its target genes include
crucial proinﬂammatory factors [23,24]. In concordance, our previous
observations on astrocytoma cells exposed to TNFα showed activation
of NF-κB and COX-2 induction as well as activation of speciﬁc
members of the MAPK family: JNK and p38-MAP kinases, in the
absence of activation of p42/p44 ERK, which in terms of biological
consequences resulted in a lack of proliferative response [25].
One interesting TNFR1 feature is the existence of a mechanism by
which it can be phosphorylated by intracellular kinases and that
modulates its downstream effector functions. In particular, it has been
described that activation of ERK by a variety of stimuli (cytokines or
growth factors) results in CD120a/TNF-R1 phosphorylation in the
absence of other adapter or signaling molecules [26]. As a conse-
quence, its role as a death receptor is impaired, although its capacity
to activate NF-κB pathway remains unaffected. Hence, these ﬁndings
suggest that the paradoxical response to TNFα may depend on
numerous environmental factors, including input from other signal-
ing pathways.
In pathological conditions, including CNS lesions or cancer
progression, cytokines are coordinately expressed and often function
synergistically, in many cases, the same molecule operating under
different circumstances or microenvironments may exert opposing
effects acting as a double-edged sword. Therefore, in this study we
focused on the simultaneous exposure of cells to sPLA2-IIA and TNFα.
Separately, they induce divergent cellular responses, and here we
propose a model that explains the outcome found upon combined
stimulation of human astrocytoma cells with both molecules.
Further understanding of the interrelationship between both
inﬂammatory mediators may shed light not only on the death/
survival decision but also on its implications on the regulation of
proinﬂammatory responses under pathological conditions.
2. Materials and methods
2.1. Materials
Plasma from patients with septicemia was obtained from venous
blood anticoagulatedwith heparin and sPLA2was puriﬁed as described
previously [15]. A C127 mouse ﬁbroblast line stably transfected with
the coding sequence of sPLA2-IIA from human placenta, kindly
provided by Dr. Olivier, was the source of human recombinant
sPLA2-IIA (hr-sPLA2-IIA) and used in some experiments to ascertain
speciﬁcity [27]. The absence of lipopolysaccharide (LPS) in the
preparation was conﬁrmed by the Limulus amebocyte lysate assay
test in the batches used for the experiments. Moreover, experiments
are conducted in the absence of FCS, which ensures that the effect is
observed in the absence of LPS binding protein, which is necessary for
the action of low concentrations of LPS. FITC-phalloidin, the inhibitor
MG132, glutathione-agarose beads and other chemicals were from
Sigma Chemical Co. (St. Louis, MO). Recombinant TNFα and the
inhibitors PD98059 andU0126were fromCalbiochem(SanDiego, CA).
GammaBind™ G Sepharose™ beads, Hybond-P membrane andradiolabelled thymidine were from Amersham Biosciences (GE
Healthcare Europe GmbH, Barcelona, Spain). Rabbit anti-MAPK
antibody reacting with both p42/p44 ERK or p42 ERK were from
Zymed Laboratories (San Francisco, CA). Rabbit phosphospeciﬁc
antibody against p42/p44 ERK was from Cell Signaling Technology,
Inc. Goat anti-human TNFR1 antibody (AF225) was from R&D Systems
(Minneapolis, MN), and anti-IκBα (sc-847), anti-IκBβ (sc-945), anti-
COX-2 (sc-1745), anti-RelA/p65 antibody (C-20) or anti-actin anti-
bodies were from Santa Cruz Inc. (Santa Cruz, CA).
2.2. Cell culture
1321N1, U373 and U118 human astrocytoma cells were grown in
DMEM supplemented with 5% FCS, 100 U/ml penicillin and 100 μg/ml
streptomycin in a 37 °C humidiﬁed incubator with 5% CO2.
2.3. Immunoﬂuorescence assays
Serum-starved 1321N1 cells (1.2×104 cells/coverslip) were
stimulated as indicated for 20–30 min, after incubation with 10 μM
U0126 or vehicle. Cells were ﬁxed for 10 min with 3.7% formalde-
hyde/PBS, washed and permeabilized for 5 min with 0.3% Triton X-
100/PBS. Actin morphology was assessed by staining with FITC-
conjugated phalloidin and visualization was performed using a Bio-
Rad laser scanning Radiance 2100 system coupled to a Nikon Eclipse
TE-2000U confocal microscope with a 60× oil objective. p65 was
detected using a rabbit polyclonal anti-RelA/p65 antibody and a
secondary antibody conjugated to FITC. Images were obtained using a
Nikon Eclipse 90i inverted ﬂuorescence microscope with a 40×
objective lens.
2.4. Analysis of apoptosis
(i) Annexin-V (DB PharMingen, San Diego, CA). After 24–36 h
treatment with the agonist, cells were resuspended in binding buffer
(10 mM HEPES, pH 7.4, 150 mM NaCl, 2.5 mM CaCl2, 1 mMMgCl2, 4%
BSA) and incubated for 30 min with 2.5 ng/ml of annexin-V FITC.
Then, cells were analyzed by ﬂow cytometry. (ii) DAPI. After 24 h
treatment with the stimuli, cells were ﬁxed, permeabilized and
stained with 10 μg/ml DAPI. Cells were visualized and photographed
with a 40× objective in a Nikon Eclipse 80i microscope. (iii)
Propidium iodide (PI). At the indicated times after stimuli treatment,
cells were collected and permeabilized with cold 70% ethanol for 24 h
and then stained with 50 μg/ml PI in the presence of RNAse. The
ﬂuorescence was measured by ﬂow cytometry.
2.5. Immunoblotting and Immunoprecipitation
Cytoplasmic extracts were isolated from 1321N1 cells (5×105
cells/well) treated different times with 100 U/ml TNFα, 1 μg/ml
sPLA2-IIA, 1 μg/ml hr-sPLA2-IIA or combination of agonist with and
without MAPK or proteasome inhibitors. For immunoprecipitation,
lysates were precleared with IgG and then incubated with the
precipitating ERK antibody overnight, followed by 1 h incubation
with GammaBind™ G Sepharose™ beads. Proteins from total cell
lysates or immunoprecipitates were separated by SDS–PAGE and
electroblotted onto Hybond-P membrane. The membranes were
stained with Ponceau to conﬁrm equal loading. Blots were probed
with diluted primary antibody and immunodetection was accom-
plished by chemiluminescence with the Amersham ECL system.
ERK band-shift was performed as described previously [15].
2.6. Flow cytometry analysis
For TNFα receptors, 1321N1 cells were incubatedwithmouse anti-
human antibodies for CD120a or CD120b (Alexis Biochemicals,
Table 1
Percentage of 1321N1 cells in the sub-G1 phase.
Percentage of cells in sub-G1 phase
100 U/ml TNF Sub-G1 phase Agonist 24 h Sub-G1 phase
Time (h)
0 6±1% Control 10±2%
8 11±4% 10 μg/ml sPLA2-IIA 3±1%
24 20±3% 100 U/ml TNF 21±3%
36 28±4% 10 μg/ml sPLA2-IIA+
100 U/ml TNF
5±2%
Cells were treated as indicated and assayed for cell cycle analysis as described in the
Materials and methods section. Apoptotic cells expressed as sub-G1 phase are
presented as median values obtained from the cells population according to the rule
G0/G1+S+G2/M=100%, calculated by WinMDI2.7 software. Each value represents
the mean±SD of at least three independent experiments.
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anti-mouse IgG and analyzed with a Coulter EPICS ﬂow cytometer.
For analysis of caspase-3 activation, cells were treated overnight
(o/n) with the indicated agonists and thenwashed and permeabilized
with 4% paraformaldehyde/0.1% Tween 20/PBS. After washing, cells
were stained with a mouse FITC-anti-active caspase-3 antibody (BD
Pharmingen, San Diego, CA) and analyzed for ﬂuorescence.
2.7. Expression and puriﬁcation of GST-fusion proteins
The plasmid of the GST-fusion protein to the N-terminus of the
cytoplasmic domain of human CD120a/TNFR1 (aa 214–435) was a
generous gift of Dr. D. Riches. The expression and puriﬁcation were
carried out as described [26]. The amount of fusion protein was
estimated by SDS–PAGE using varying amounts of BSA as a standard,
followed by staining with Coomassie blue.
2.8. In vitro endogenous MAPKs binding to GST-CD120a(214–435)
Binding of MAPKs to GST-TNFR1 cytoplasmic domain fusion
protein was determined by an in vitro pull-down assay. After
stimulation, 1321N1 astrocytes were rinsed and lysed in 500 μl of
Nonidet P-40 lysis buffer (50 mM Tris/HCl buffer, pH 7.4, containing
10 ml/L Nonidet P-40, 100 ml/L glycerol, 50 mM NaCl, 5 μg/ml
aprotinin, 1 mM PMSF, 10 μg/ml leupeptin, 1 mM NaF and 1 mM
Na3VO4). Cellular debris was removed and the supernatants were
incubated with 20 μl of GST-Sepharose beads or GST-CD120a(214–435)
protein-Sepharose beads for 2 h at 4 °C. The beads were then washed
and resuspended in Laemmli sample buffer containing 100 mM
dithiothreitol. The samples were separated on a 10% SDS–polyacryl-
amide gel and transferred to PVDF membranes. Immunodetection of
boundMAPKswas detected using speciﬁc antibodies, either anti-p42/
p44, anti-p38 or anti-JNK antibodies or anti-phosphospeciﬁc p42/p44
antibody and the Amersham ECL system. In experiments in which in
vitro kinase assays were performed, after the last wash, the beads
were resuspended in 40 μl of PAN buffer (10 mM Pipes buffer, pH 7.0,
containing 100mMNaCl and 10 μg/ml aprotinin) to bring themixture
up to 60 μl and then used as described below.
2.9. In vitro kinase assay
The kinase assays were performed at 30 °C for 30 min in kinase
buffer (10 mM Pipes buffer, pH 7.2, containing 10 mM MnCl2 and
20 μg/ml aprotinin) together with 10 μCi of [γ32P]ATP. The kinase
reactions were terminated by the addition of 20 μl of 5× Laemmli
sample buffer containing 100 mM dithiothreitol. The mixtures were
separated by SDS–PAGE. Phosphorylated GST-CD120a(214–435) was
detected by autoradiography.
2.10. SYBR green real-time PCR and standard RT-PCR for COX-2 mRNA
expression
Total cellular RNA was isolated from 1321N1 cells using TRIzol
reagent (Life Technologies, Gaithersburg, MD) and was reverse
transcribed with AMV reverse transcriptase (Roche Applied Science,
Barcelona, Spain). Primers for COX-2 and β-actin were (1) COX-2 sense
5′-TTC AAA TGAGAT TGTGGGAAAATTGCT-3′; (2) COX-2 antisense 5′-
AGA TCA TCT CTG CCT GAG TAT CTT-3′; (3) β-actin sense 5′-CTG TCT
GGCGGCACCACCAT-3′; and (4)β-actin antisense 5′-GCAACTAAGTCA
TAG TCC GC-3′. Real-time PCR was performed using the Light Cycler-
Faststart DNA master SYBR Green I kit (Roche Diagnostics, Barcelona,
Spain) with the Light Cycler™(Roche Diagnostics, Barcelona, Spain) at
the following cycling parameters: initial denaturing for 5 min at 95 °C,
followedby50cycles of 5 s at 95 °C, 5 s at 60 °Cand18s at72 °C. Theﬁnal
cycle was followed by a melting curve analysis to verify the
ampliﬁcation of a single product in each well.Each assay included a relative standard curve, cDNA samples, a no-
reverse-transcribed control and a no-template control. The relative
standard curve was generated by serial ﬁvefold dilutions of cDNAs
obtained from 1321N1 cells treated with 100 U/ml TNFα for 6 h to
induce high levels of COX-2 expression. All samples were run in
triplicate, and the relative expression values of COX-2 were
normalized to the endogenously expressed housekeeping gene, β-
actin, using the delta Ct method (LightCycler software—version 4.0).
Quantitative real-time PCR experiments were performed three times,
and the results were averaged. No ampliﬁed product was detected
from negative control RNA samples to which reverse transcriptase
was not added.
Standard PCR was performed in an Eppendorf Personal Master-
clycler as previously described [25]. Multiplex PCR products were
resolved by electrophoresis through an agarose gel and visualized by
ethidium bromide staining.
2.11. Data presentation
Each set of experiments was repeated at least three times with
similar results. Unless otherwise indicated, the data presented are
from representative experiments. Numerical data are expressed as
means±SE and analyzedwith the GraphPad Prism Version 4 software
(San Diego, CA) for statistical signiﬁcance using analysis of variance
(ANOVA) followed by the Bonferroni's multiple comparison test. A p
value b0.05 was considered signiﬁcant.
3. Results
3.1. sPLA2-IIA abrogates TNFα-induced apoptosis in 1321N1 astrocytoma
cells
Considering 1321N1 cells do not express endogenous sPLA2-IIA
(Hernandez, M., Sanchez-Crespo, M. and Nieto, M.L., unpublished
work), the responses obtained will be elicited by exogenously added
sPLA2. Upon this statement, the effect of sPLA2-IIA treatment in TNFα-
induced cell death was studied using different approaches. TNFα-
stimulated 1321N1 astrocytoma cells were subjected to various
apoptosis assays, including cell cycle analysis, DAPI staining and
annexin-V binding. We ﬁrst performed cell cycle analysis using the
propidium iodide assay as a measure for DNA content of the cells.
Table 1 shows that incubation of 1321N1 cells with 100 U/ml TNFα
decreased cell viability in a time-dependent manner. After 24 h of
TNFα treatment, we observed a subdiploid peak of DNA (apoptotic
peak) of cells accumulated at the sub-G1 phase and by 36 h the
population with a sub-G1 DNA content increased from 6% in the
control culture to 28% in the stimulated culture. To detect the
characteristic morphological changes of apoptosis as nuclear frag-
mentation and chromatin condensation, cells were stained with DAPI
(Fig. 1A). 1321N1 cells treated with 100 U/ml of TNFα for 24 h and
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Fig. 2. Effect of ERK inhibition on sPLA2-IIA protective effect of the 1321N1 cells. (A) Astrocytes were stimulated with 100 U/ml TNFα, 1 μg/ml sPLA2-IIA, 1 μg/ml hr-sPLA2-IIA or
100 U/ml TNFα plus 1 μg/ml of sPLA2-IIA for 10min, and cell lysates were collected to assay either the characteristic band-shift of the phosphorylated protein using a rabbit anti-p42
antibody or in standard gels using a rabbit phosphospeciﬁc p42/p44 antibody. 1321N1 cells were stimulated for 24 h with 100 U/ml TNFα or 100 U/ml TNFα plus 1 μg/ml of sPLA2-
IIA, in the absence or presence of 10 μM of the MEK inhibitor U0126. Afterwards, the cells were stained with FITC-phalloidin and examined by confocal microscopy using a 60× oil
objective (B), and annexin-V FITC (C) or active caspase-3-FITC (D) and analyzed by ﬂow cytometry. Results are expressed as the mean±SE (n=4; ⁎pb0.01 versus TNFα alone;
⁎⁎pb0.05 versus TNFα+sPLA2-IIA without inhibitor). To facilitate comparison, numerical data are calculated subtracting the % positives resting untreated cells to the value (%)
obtained with each treatment condition.
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condensed and fragmented nuclei and reduction of cell volume. This
apoptotic response was further conﬁrmed by experiments using
annexin-V staining, which detects early apoptotic events such as
plasma membrane asymmetry. An increase in the number of
positively stained cells was observed 24 h after TNFα incubation
(Fig. 1B). The percentage of apoptotic cells varies between experi-
ments due to biological variance.Fig. 1. Effect of sPLA2-IIA on TNFα-apoptotic astrocytes. 1321N1 cells were stimulated with 1
of sPLA2-IIA and cultured for 24 h. After treatment, (A) cells were stained with DAPI and e
analyzed by ﬂow cytometry or (C) cells were permeabilized and incubated with anti-active
with 100 U/ml TNFα, 1 μg/ml sPLA2-IIA or 1 μg/ml sPLA2-IIA added either 5 or 10 min bef
matching antibody, and black-open peaks show the ﬂuorescence of cells treated as indicateSince cells undergo apoptosis through the activation of the caspase
cascade, and this caspase family is synthesized as pro-forms that are
proteolytically cleaved and activated during apoptosis, we looked for
the presence of the active effector caspase, caspase-3. As shown in Fig.
1C, TNFα treatment for 24 h certainly increased active caspase-3
formation as determined by FACScan cytometry.
When astrocytoma cells were incubated in the simultaneous
presence of sPLA2-IIA and TNFα, the percentage of sub-G1 fraction00 U/ml TNFα, 1 μg/ml sPLA2-IIA, 1 μg/ml hr-sPLA2-IIA or 100 U/ml TNFα plus 1 μg/ml
xamined by ﬂuorescence microscopy, (B) cells were stained with annexin-V FITC and
caspase-3 antibody and analyzed by ﬂow cytometry. (D) Cells were stimulated for 24 h
ore or after 100 U/ml TNFα. Gray-solid peaks show the ﬂuorescence of an IgG isotype
d in the histogram. Values are mean±SE of three experiments.
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similar to sPLA2-IIA-treated cells (Table 1). The results from the
annexin-V and DAPI staining experiments also showed a notably
reduced number of apoptotic cells when 1321N1 cells were
stimulated with TNFα in the presence of sPLA2-IIA. Fig. 1 shows a
clear reduction of apoptotic cells: annexin-positive cells almost
disappear (Fig. 1B) and nuclei look round and homogeneous (Fig.
1A). In addition, a considerable diminished presence of activated
caspase-3 was observed (Fig 1C). We also performed DAPI and
annexin-V assays with human recombinant sPLA2-IIA (hr-sPLA2-IIA)
obtained from C127 cells stably transfected with the coding sequence
of sPLA2-IIA from human placenta, ﬁnding a very similar, if not
identical results. We then evaluated the signiﬁcance of the time in
which sPLA2-IIA is administrated to the cells – before or after TNFα –
on its anti-apoptotic actions by an annexin-V binding assay. The data
demonstrated that while the addition of 1 μg/ml sPLA2-IIA before or at
the same time as TNFα inhibited the TNFα-induced annexin-positive
cells, when sPLA2-IIA was administrated 10 min or 5 min after TNFα
stimulation, the phospholipase blocked none of the TNFα-mediated
apoptotic cell death. Thus, pointing to a biochemical mechanism
highly regulated by the sPLA2-IIA in the upstream pathway of TNFα-
induced cell death.
This effect of sPLA2-IIA counteracting the apoptotic death induced
by TNFα not only includes abrogation of the programmed cell death
response but also preservation of sPLA2-IIA proliferating ability. In
previous studies from our lab, experiments of [3H]thymidine
incorporation were used to determine cell proliferation and we
demonstrated that incubation of 1321N1 cells with sPLA2-IIA
promotes proliferative activity in the cells [15]. In the present assay,
we have observed that, while the radioactivity incorporated in TNFα-
treated cells was similar to serum-starved cells, the simultaneous
addition of sPLA2-IIA and TNFα-stimulated [3H]thymidine uptake
(18.860+750dpmcontrol, 30.461+1.212dpmTNFα, 196.995+20.569
dpm sPLA2-IIA and 286.595+16.793 dpm sPLA2-IIA+TNFα). These
results indicate that sPLA2-IIA, besides protecting cells from TNFα-
induced apoptosis, it also maintains, even in the presence of TNFα, its
ability to induce proliferation of human 1321N1 astrocytoma cells.
3.2. Inhibition of ERK phosphorylation suppresses sPLA2-IIA protective
effect against cell death
In an attempt to identify the intracellular signaling pathways
involved in this phenomenon, we ﬁrst investigated the possible
activation of MAPKs as the most likely mechanism since studies in
different cell lines have reported that ERK activation protects
against cell death. To determine the participation of ERK signaling
cascade in the blocking effects of sPLA2-IIA during TNFα-toxicity, we
ﬁrst determined the effect of TNFα on sPLA2-IIA-induced ERK
phosphorylation. 1321N1 cells were stimulated for different times
with 1 μg/ml sPLA2-IIA alone, 1 μg/ml hr-sPLA2-IIA alone or in
combination with 100 U/ml TNFα. The presence of TNFα did not
affect the level of phosphorylation induced by sPLA2-IIA alone, as
judged by the appearance of the characteristic band-shift due to the
phosphorylation of the protein and further conﬁrmed using a
phosphospeciﬁc antibody against p42/p44 ERK (Fig. 2A). Next, we
pretreated the cells for 30 min with different doses of the MEK1
inhibitor U0126 to block ERK phosphorylation and, although no
effect on TNFα-mediated apoptosis was observed, the protective
action of sPLA2-IIA was inhibited. We found that the presence of the
MEK1 inhibitor increased the number of apoptotic cells (Fig. 2B)
and the levels of active caspase-3 (Fig. 2C) in cells stimulated with
the combination of sPLA2-IIA+TNFα for 24 h. A total blockage of
the protective sPLA2-IIA effect was observed at 10 μM U0126, while
no apoptotic signiﬁcant cell death was observed when 1321N1
astrocytoma cells were incubated with U0126 in the presence of
sPLA2-IIA alone.3.3. sPLA2-IIA-activated ERK prevents actin depolymerization induced
by TNFα
Another morphological alteration observed when cells became
apoptotic was actin microﬁlament bundle disruption and stress ﬁber
dissolution, likely due to cellular retraction and loss of adhesion.
Moreover, it has been reported that actin is one of the numerous
proteins that can be degraded by caspases during apoptotic cell death.
To determine the role of sPLA2-IIA and its cytoprotective effect on
actin microﬁlament rearrangement, 1321N1 cells were incubated
with sPLA2-IIA, TNFα or combined addition of both agonists for
30 min and stained with FITC-phalloidin to visualize ﬁlamentous F-
actin by immunoﬂuorescence microscopy. As shown in Fig. 2D,
treatment with TNFα promoted disorganization of actin ﬁlaments,
while sPLA2-IIA caused stress ﬁber formation, in the absence, as well
as in the presence of TNFα.
To deﬁne the role of ERK in sPLA2-IIA-mediated actin rearrange-
ment, 1321N1 cells were pretreated with 10 μM U0126 for 30 min
prior to stimulation with the agonists for an additional 30 min. In Fig.
2D, we show that the MAPK inhibitor only prevented sPLA2-IIA-
mediated actin rearrangements when TNFα was also present in the
culture medium. These results suggest that ERK is not involved in
sPLA2-IIA-mediated actin remodeling in 1321N1 cells; however, it is
involved in preventing cytoskeletal ﬁlament disorganization induced
in TNFα-apoptotic astrocytes.
3.4. sPLA2-IIA-activated ERK phosphorylates TNFα receptor CD120a
in vitro
To investigate the mechanism/pathway through which ERK exerts
the above mentioned effect, we considered the ﬁndings previously
reported [26,28]. Thus, it has been described, that CD120a/TNFR1 is a
target of activated ERK and, upon phosphorylation the receptor looses
its apoptotic activity, while preserving its ability to activate NF-κB. In
this context, we investigated whether this mechanism was involved
in the dominant pro-survival signal induced by sPLA2-IIA in 1321N1
astrocytoma cells.
Weﬁrst analyzed the TNFα receptor subtypes expressed in 1321N1
cells by ﬂow cytometry. We found protein expression of CD120a/
TNFR1, whereas CD120b/TNFR2 was not detected (Fig. 3A). Next, we
investigated the capacity of endogenous ERK to interact both, with
the cell receptor CD120a and with the GST-CD120a(214–435) fusion
protein. As shown in Fig 3B, stimulation of 1321N1 cells with
sPLA2-IIA, alone or in the presence of TNFα, caused interaction of
phosphorylated ERK with TNFR1, identiﬁed by coimmunoprecipita-
tion. Although we used anti-p42/p44 ERK antibody to immuno-
precipitate, only one isoform could be observed phosphorylated,
this could be due to conformational differences or antibody
speciﬁcity. Further experiments using different antibodies will be
performed to determine the precise role of both isoforms in the
complex. We also investigated the capability of endogenous sPLA2-
IIA-activated ERK to bind to and phosphorylate CD120a/TNFR1.
1321N1 cells were stimulated with 1 μg/ml sPLA2-IIA for different
times and the cellular lysates were incubated with the GST-
CD120a(214–435) fusion protein bound to glutathione-Sepharose
beads. After washing the beads, proteins were separated by SDS–
PAGE. Fig. 3C shows the results of Western blots demonstrating
that p42/p44 ERK are rapidly activated by sPLA2-IIA, as expected,
and bind to the receptor fusion protein; however, neither JNK nor
p38 bind to the GST-CD120a(214–435)-coated beads. Moreover, this
binding is independent of the phosphorylation/activation state of
the protein since we found ERK-GST-CD120a(214–435) interaction in
both resting and sPLA2-IIA-activated lysates. Furthermore, the in
vitro kinase assay showed a rapid and transient increase in the
phosphorylation of the fusion protein, which paralleled with the
time course of activation of ERK. Indeed, the presence of the MEK
Fig. 3. TNFR expression in 1321N1 cells (A). TNFR1 and TNFR2 were detected with
mouse mAb H398 IgG2a and 80M2 IgG1, respectively, and in each panel it is compared
with irrelevant antibody binding. Solid gray curves represent the binding of irrelevant
antibody and open black curves the expression of the receptors. (B) Cells were
stimulated with the agonists for 10 min. Lysates were immunoprecipitated with anti-
ERK, probed with anti-TNFR1 and reprobed with anti-pERK. Heavy chain IgG was used
as a control loading. (C) Cells were stimulated with 1 μg/ml of sPLA2-IIA for the
indicated times, lysed and incubated with GST-CD120a(214–435) beads or control GST
beads. After extensive washing, the beads were used, either for the immunodetection of
the three MAPKs, p38, JNK and p42/p44, using speciﬁc antibodies, or for an in vitro
kinase assay. (D) Cells were treated as indicated in the presence or absence of 10 μM
U0126, lysed, incubated with GST-CD120a(214–435) beads or control GST beads and used
for immunodetection of p-p42/p44 or for an in vitro kinase assay. Results shown are
representative of three independent experiments.
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also inhibited the phosphorylation of the GST-CD120a(214–435)
fusion protein (Fig. 3D). No presence or phosphorylation ofMAPKs was detected in the GST-coated Sepharose beads alone at
any time point.
We also found herein that the ability of the TNFα receptor,
CD120a/TNFR1, to activate NF-κB remained unaffected in the
presence of sPLA2-IIA. Furthermore, up-regulation of proteins depen-
dent of NF-κB activation, as COX-2, observed after TNFα-treatment
was further increased by the presence of either sPLA2-IIA. COX-2 up-
regulation and NF-κB activation were monitored by immunoblot
analysis. Thus, in cytosolic extracts of 1321N1 cells, we analyzed the
expression levels of COX-2 as well as of IκBα and IκBβ proteins that
block NF-κB activation. As shown in Fig. 4A, control astrocytoma cells
expressed the inhibitory units of NFκB, IκBα and IκBβ. After TNFα
stimulation, the levels of both proteins decreased, as expected, while
sPLA2-IIA or hr-sPLA2-IIA treatment did not affect their expression.
We also observed that the simultaneous presence of sPLA2-IIA and
TNFα led to a rapid and transient decrease of the inhibitory proteins,
similar to what we found with TNFα alone.
In addition, since NFκB activation requires nuclear translocation of
the RelA/p65 subunit, 1321N1 cells were stained with anti-p65
antibody and visualized using a ﬂuorescent microscopy. In resting
conditions as well as upon 1 μg/ml sPLA2-IIA or 1 μg/ml hr-sPLA2-IIA
treatment (30 min), p65 was localized mainly in the cytoplasm (Fig.
4B). However, after a 30-min treatment with 100 U/ml TNFα, there
was extensive nuclear staining for the p65 protein, which indicated
the accumulation of RelA/p65 in the nuclei. The presence of sPLA2-IIA
or hr-sPLA2-IIA did not modify the nuclear translocation induced by
TNFα.
With regard to COX-2 regulation, and as shown in Fig. 5A, while
TNFα exposure induced high levels of COX-2 protein, sPLA2-IIA or
hr-sPLA2-IIA were unable to stimulate its expression when
presented alone. However, maximal production was achieved
when 1321N1 astrocytes were simultaneously challenged with
TNFα and sPLA2-IIA. This cooperative response was associated
with ERK activation since the presence of the MEK inhibitors U0126
or PD98059 blocked the synergistic effect induced by the co-
stimulation, without affecting the TNFα response. We also tested
other inhibitors that are known to block NF-κB activation, such as
the proteasome inhibitor MG132, ﬁnding a complete abrogation of
the TNFα response, either alone or in combination with the sPLA2-
IIA. Nevertheless, this synergy found at the translational level could
not be appreciated at the transcriptional level. In Fig. 5B, we show
COX-2 gene expression determined by SYBR green real-time PCR
and semiquantitative multiplex RT-PCR. We found that COX-2
mRNA levels were increased in TNFα-stimulated cells compared
with control cells, but no further shifts in the relative amounts COX-
2 mRNA were observed by the simultaneous presence of TNFα and
sPLA2-IIA when compared to cells treated with TNFα alone.
Furthermore, pretreatment with the MEK/ERK inhibitor U0126, at
the concentrations which abrogate p42/p44 protein phosphoryla-
tion, did not produce signiﬁcant effects on COX-2 gene expression
induced after agonist challenge.
3.5. sPLA2-IIA effect on TNFα signaling is not restricted to 1321N1 cells
To rule out the possibility of a cell line-speciﬁc phenomenon, we
examined the ability of sPLA2-IIA to block the apoptotic death induced
by TNFα in two additional human astrocytoma cell lines, U373 and
U118. After exposure of the cells to TNFα, sPLA2-IIA or the
simultaneous presence of both, the cell lines were assayed for
annexin-V. Although the extent of the effects observed varied from
cell to cell, all cell types under study were found to bind annexin-V to
a signiﬁcantly higher degree in TNFα-treated cells than in resting
control cells. In the presence of sPLA2-IIA, a clear reduction in the
number of annexin-V-positive cells was observed, indicating that in
all of them the phospholipase protected from the programmed cell
death induced by TNFα (Fig. 6).
Fig. 4. Effect of sPLA2-IIA on TNFα induces NFκB activation. (A) Immunodetection of IκB proteins in 1321N1. Cells were stimulated with 100 U/ml TNFα, 1 μg/ml sPLA2-IIA, 1 μg/ml
hr-sPLA2-IIA or 100 U/ml TNFα plus 1 μg/ml of sPLA2-IIA for the times indicated, and at the end of these periods, cell lysates were used for SDS–PAGE and immunodetection of IκBα
and IκBβ. (B) Immunocytochemical staining using a RelA/p65 antibody. Cells were stimulated with 100 U/ml TNFα, 1 μg/ml sPLA2-IIA, 1 μg/ml hr-sPLA2-IIA or 100 U/ml TNFα plus
1 μg/ml of sPLA2-IIA for 30 min. Then, cells were ﬁxed and immunocytochemistry was performed using anti-RelA/p65 antibody.
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In the context of CNS disorders, numerous factors play a role in
dictating the response of any speciﬁc cell type to the local inﬂammatoryFig. 5. Effect of sPLA2-IIA on TNFα induces COX-2 up-regulation. Cells treated under the show
real-time PCR and standard PCR (N). Values are normalized to β-actin. Numerical data areenvironment. Since it is the integration of multiple extracellular signals
which determines the ﬁnal outcome, a great deal is to know about the
signaling transduction networks involved in the response to the
simultaneous stimulation with more than a single agonist.ed conditions for COX-2 immunodetection (A) or COX-2 mRNA induction measured by
expressed as the mean±SE.
Fig. 6. Effect of sPLA2-IIA on TNFα-apoptotic astrocytes. U118 and U373 cells were
stimulated with 100 U/ml TNFα, 1 μg/ml sPLA2-IIA or 100 U/ml TNFα plus 1 μg/ml of
sPLA2-IIA and cultured for 24 h. After treatment, cells were stained with annexin-V FITC
and analyzed by ﬂow cytometry. Labeling obtained after treatment (open black curves)
is compared with that of cells treated with vehicle alone (gray-ﬁlled curves).
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paradoxical proinﬂammatory molecules sPLA2-IIA or TNFα elicit
distinct signaling events associated with their ability to promote or
not a proliferative response [15,16,25]. Here, we study the transduc-
tion pathways triggered by the simultaneous exposure of astrocytoma
cells to them, ﬁnding an interference of sPLA2-IIA into TNFα signaling
network.
For the ﬁrst timewe show a role for sPLA2-IIA in cellular protection
abrogating TNFα-induced apoptosis. We demonstrate that the
secreted phospholipase, not only suppresses TNFα-induced apoptoticFig. 7. Proposed model of sPLA2 and TNFα signalfeatures, such as disruption of the cytoskeleton, condensation of
chromatin and fragmentation of DNA as well as activation of caspase-
3, but also preserves cellular growth.
Protective effects of different molecules on TNFα-induced apo-
ptosis have been documented in several cell types. Preincubation of
U937 cells with docosahexaenoic acid or Vitamin E greatly attenuates
TNFα-induced apoptosis [29]. Exogenous administration of CO
dramatically inhibits TNFα-mediated liver injury in vivo and
hepatocyte cell death in vitro [30]. Moreover, C-peptide and insulin
protect against TNFα-induced proximal tubular cell toxicity and
apoptosis [31]. Furthermore, human epidermal growth factor sup-
presses TNFα-mediated accumulation of p53 and induction of
apoptosis in the human cervical carcinoma cell line, ME180S [32].
Regarding mammalian secreted phospholipases A2, their precise
role in cell survival has not been clariﬁed yet. Several reports indicate
that they might display apoptotic or anti-apoptotic activities
depending on the isotype and the cell type. In neurons, sPLA2s from
group IB, IIA and III promote an apoptotic response [33-35], and even
there is an enhancement of glutamate-induced cell death in the
presence of group III [36]. However, in non-neural cells, no toxic effect
is observed for sPLA2-IIA [33] in fact, it elicits mitogenic responses in
1321N1 cells [15], and groups IB and III may enhance mast cell
survival [37]. The sPLA2-IIA anti-apoptotic activity is not unique for
1321N1 cells, but it has also been observed in other well-character-
ized human astrocytoma cell lines. In this study we also ﬁnd that,
while resting 1321N1 cells exhibit no prominent actin ﬁlaments,
treatment with sPLA2-IIA elicits a signiﬁcant augmentation of F-actin
cables and stress ﬁbers. In keeping with published studies about
cytoskeletal protein remodeling induced by conventional growth
factors, these actin ﬁbers might well be playing a crucial role in cell
cycle progression, proliferation and/or survival [38].
Recently, it has been reported that apoptotic death occurs in
cycloheximide-sensitized 1321N1 cells after exposure to TNFα [39]. In
the present study, we observe, without any sensitization treatment,
that the activation through TNFα receptors induces apoptotic
features. However, we ﬁnd that TNFα induces NFκB activation,
which might promote anti-apoptotic effects depending on the cells,ing interaction in 1321N1 astrocytoma cells.
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activation. Then, the pro- or anti-apoptotic effects observed in this
study should be explained through the modulation of alternative
pathways, independently of NFκB activation. Consistent with this
hypothesis, our previous work shows that sPLA2-IIA, as well as TNFα,
initiates a variety of intracellular signaling routes, which are
important for cell survival [15,16,25]. Thus, one of the most
intensively studied signal transduction pathways, the MAP kinase-
related cascade, has been reported to be activated by both agonists,
although with distinct patterns depending on the members of each
MAPK sub-family. sPLA2-IIA induces a rapid and transient activation of
the three MAPK subgroups (JNK, p38 and ERK), whereas TNFα
induces a biphasic enhancement of JNK and p38 activity in the
absence of activation of ERK at any time [25]. These differences in the
proﬁle of activation (transient or sustained) might determine the type
of cellular response evoked. In the present study we show that,
although TNFα does not induce ERK activation, when both signal
inputs are given simultaneously, the mitotic MAPK pathway is
activated to the same extent as observed after sPLA2-IIA stimulation
alone. This ﬁnding might support a role for phosphorylated ERK in the
initiation of signals leading to the reversal of TNFα toxicity.
With regard to TNFα binding to 1321N1 cells, it should be stressed
that basal levels of TNFR1, but not TNFR2 expression are found in this
cell line, therefore all the effects observed, undoubtedly involve
TNFR1-based signaling. It is well established that the signaling
cascades that are initiated by clustering of TNFR1 depend on the
recruitment of different adaptor molecules with the receptor death
domain, and several studies [26,28] have shown that ERK is capable of
binding and phosphorylating sequences present within the cytoplas-
mic domain of the TNFR1 and that phosphorylation results in a loss of
the ability of the receptor to induce apoptosis, while its capacity to
activate NFκB is preserved. In this context, the present study shows
that sPLA2-IIA-induced protection is dependent on ERK activity since
pharmacological inhibition of the ERK pathwaywith U0126 blocks the
protection. In addition, coimmunoprecipitation studies reveal direct
interaction of ERK with TNFR1 in response to stimulation with sPLA2-
IIA, either alone or in the presence of TNFα. Moreover, using the
fusion protein GST-CD120a(214–435), we have shown that ERK,
independently of its activation status, interacts with this cytoplasmic
domain of TNFR1. Furthermore, in an in vitro kinase assay, lysates
from sPLA2-IIA-stimulated astrocytes were able to phosphorylate
GST-CD120a214–435. This phosphorylation is abrogated in the presence
of the ERK inhibitor, U0126. We also considered the possible presence
of other members of the MAPK family, such as p38 or JNK, which
present the same phosphorylation consensus sequence, ﬁnding none.
Because of that, and in keeping with previously reported studies, we
propose that the activation of ERK by sPLA2-IIA is intimately linked to
the mechanism by which the apoptotic activity of this receptor is
regulated. According to this, the important role in cell survival of ERK-
mediated phosphorylation of TNFR1 has also been documented in
macrophages in response to different agents [40]. This agrees with our
kinetic data since an efﬁcient prevention of the apoptotic response
required the coordinated presence of both agonists. This preventive
effect was insufﬁcient or not observed when sPLA2-IIA was added to
cells pretreated with TNFα, thus indicating that a prompt but precise
and effective ERK-mediated phosphorylation of TNFR1 is a biochem-
ical step required for the maximal occurrence of sPLA2-IIA-mediated
abrogation of the TNFα-induced cell death.
Interestingly, in a recently published study [41], it is shown that
TNFα induces ERK phosphorylation and proliferation in astrocytoma
cells. It is precisely ERK activation whichmight explain the discrepancy
with our ﬁndings, since the authors claim ERK as responsible of
proliferation, whilst we ﬁnd no ERK activation at any time after
exposure of the cells to TNF, neither now, nor in earlier studies [25].
It is also worth pointing out that, although several studies have
shown that agonist-mediated actin stress ﬁber formation may beattenuated by inhibitors of p42/p44 ERK, the effect of sPLA2-IIA on
actin rearrangement is only ERK sensitive when combinedwith TNFα,
suggesting that in our model the role of ERK in cytoskeletal regulation
is linked to the phosphorylation of TNFR1. Meanwhile, the possible
regulatory mechanism involved in the actin microﬁlament organiza-
tion in astrocytoma cells after sPLA2-IIA treatment is ERK
independent.
In contrast to the sPLA2-IIA abrogation of the apoptotic hallmarks,
NFκB activation induced by TNFα is not attenuated by the presence of
the phospholipase. In fact, COX-2, a TNFα-up-regulated protein
through an NFκB-dependent pathway is not only preserved but
further increased by the presence of sPLA2-IIA, even though sPLA2-IIA
has no effect on its own. This means that both agonists may act in
concert to regulate the expression of proinﬂammatory proteins and
signaling molecules, other than NFκB, are involved in the synergistic
effect. Because the presence of the inhibitors PD 98059 or U0126
strongly blocks the cooperative effect, a participation of MEK/ERK is
highlighted. Several molecular events from transcription, post-
transcription to protein turnover, have been implicated in the control
of COX-2 expression. Our results suggest that the synergistic
expression of COX-2 protein observed may be regulated at the level
of post-transcription or protein turnover since no differences at the
transcriptional level were found. Recent reports implicate mRNA
stability and translational efﬁciency as central controls in COX-2
protein induction [42]. Growing evidence points to stimulation of
MAPKs signaling pathway, including ERK [43], as an event that
inﬂuences its expression at a post-transcriptional step. Indeed,
alterations in the ubiquitin–proteasome pathway, the principle
mechanism responsible for the turnover of short life proteins, may
contribute to increase the accumulation of COX-2 protein by
preventing its degradation [44], in fact, it has been reported that the
ERK cascade stabilizes different proteins through the inhibition of the
ubiquitin–proteasome pathway [45,46]. Future studies will be
directed towards obtaining a better understanding of the downstream
pathway and molecular mechanisms responsible for this type of post-
transcriptional regulation induced by the simultaneous presence of
sPLA2-IIA and TNFα in astrocytoma cells.
In summary, these ﬁndings support a model put forward in Fig. 7
where sPLA2-IIA reveals as a protein with a multifunctional role.
Through the activation of ERK, it confers to 1321N1 astrocytoma cells
the ability to resist TNFα-induced apoptosis by acting both on early
signs of apoptosis (e.g., plasma membrane asymmetry) as well as on
its latter manifestations (e.g., caspase-3 activation), and it has a
pronounced effect on the generation of synergic inﬂammatory
responses. All these data show a cross-talk involving different
signaling pathways, which stresses the importance of studying
cytokines in a microenvironmental context and suggests the impor-
tance of evaluating the interactions between inﬂammatory cytokines
under pathological circumstances.Acknowledgements
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